Intervention Review

You have free access to this content

Mitoxantrone for multiple sclerosis

  1. Filippo Martinelli Boneschi1,*,
  2. Laura Vacchi2,
  3. Marco Rovaris3,
  4. Ruggero Capra4,
  5. Giancarlo Comi5

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group

Published Online: 31 MAY 2013

Assessed as up-to-date: 30 MAY 2013

DOI: 10.1002/14651858.CD002127.pub3


How to Cite

Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD002127. DOI: 10.1002/14651858.CD002127.pub3.

Author Information

  1. 1

    INSPE - San Raffaele Scientific Institute, Department of Neurology, Milano, Italy

  2. 2

    Scientific Institute and University Ospedale San Raffaele, Institute of Experimental Neurology (INSPE), Milano, Italy

  3. 3

    I.R.C.S.S. S. Maria Nascente - Fondazione Don Gnocchi, U.O. Sclerosi Multipla, Milano, Italy

  4. 4

    Spedali Civili, Brescia, Italy

  5. 5

    San Raffaele Hospital, Department of Neurology, Milano, Italy

*Filippo Martinelli Boneschi, Department of Neurology, INSPE - San Raffaele Scientific Institute, Via Olgettina, 48, Milano, 20131, Italy. filippo.martinelli@hsr.it.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 31 MAY 2013

SEARCH

[Figure 1]
Figure 1. Flow diagram up to 23 May 2013.
[Figure 2]
Figure 2. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
[Figure 3]
Figure 3. Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Mitoxantrone versus placebo: primary outcomes, Outcome 1 Patients with 6-month confirmed disability progression at 2 years.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Mitoxantrone versus placebo: primary outcomes, Outcome 2 Post-hoc analysis: Patients with 3- or 6-month confirmed disability progression.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Mitoxantrone versus placebo: primary outcomes, Outcome 3 Patients who withdrew from the study because of major side effects of the drug.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Mitoxantrone versus placebo: secondary outcomes, Outcome 1 Patients with no relapses at 6 months/1 year.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Mitoxantrone versus placebo: secondary outcomes, Outcome 2 Mean change in disability (EDSS).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Mitoxantrone versus placebo: secondary outcomes, Outcome 3 Patients with no relapses at 2 years.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Mitoxantrone versus placebo: secondary outcomes, Outcome 4 Annualized relapse rate.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Mitoxantrone versus placebo: secondary outcomes, Outcome 5 Number of MRI active lesions.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Mitoxantrone versus placebo: secondary outcomes, Outcome 6 Number of patients with active lesions.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Mitoxantrone versus placebo: adverse events, Outcome 1 Amenorrea.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Mitoxantrone versus placebo: adverse events, Outcome 2 Nausea/Vomiting.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Mitoxantrone versus placebo: adverse events, Outcome 3 Alopecia.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Mitoxantrone versus placebo: adverse events, Outcome 4 Urinary tract Infections.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Mitoxantrone versus placebo: adverse events, Outcome 5 Respiratory tract infections.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Mitoxantrone versus placebo: adverse events, Outcome 6 Headhache.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Mitoxantrone versus placebo: abnormal laboratory values, Outcome 1 Leucopenia.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Mitoxantrone versus placebo: abnormal laboratory values, Outcome 2 Anemia.